Volume Alert - AGIO 94.60 Agios Pharmaceuticals Inc $AGIO

New Post Public Reply Private Reply Replies (0) Message Board

Nov 19, 2014 at 1:04 PM

Volume Alert - AGIO 94.60 Agios Pharmaceuticals Inc $AGIO Hit a high today of 95.18 Closing the day 10:30 at 94.60 +10.79 +12.87% With a day low of 83.68 and a total volume of 1,790,245.

AGIO Recent Posts: http://investorshangout.com/Agios-Pharmaceuti...GIO-90049/

AGIO Agios Pharmaceuticals Inc Recent Headline News

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - 8 mins ago

CLUB: 6.06 (+0.51), LEJU: 12.23 (-1.93), ANV: 1.77 (-0.27), SSI: 18.62 (+2.88), ROX: 1.53 (-0.25), CLF: 8.75 (-1.46), BIND: 8.57 (-1.98), NADL: 3.29 (-0.68), CSTM: 17.01 (-3.96), VRML: 1.48 (+0.11), WTT: 2.63 (-0.28), CANF: 3.95 (+0.95), DL: 17.98 (+3.01), BAMM: 1.79 (+0.22), RELV: 1.32 (+0.13), SNCR: 42.45 (-5.16), ATLC: 2.64 (+0.33), AGIO: 95.61 (+11.80), BBLU: 1.09 (-0.10), OPLK: 24.18 (+2.93)

Cramer: Agios Pharmaceuticals' Leukemia Drug Pushing Stock 'Much Higher'
at The Street - 1 hr 42 mins ago
TheStreet's Jim Cramer says Agios Pharmaceuticals' positive Phase 1 data for its leukemia treatment is impressive. As a result, shares are going higher despite doubling since July.
AGIO: 95.61 (+11.80), CELG: 107.56 (+0.78)

Stock Futures Take A Data Dive; Tesla Falls On Outlook Change
at Investor's Business Daily - Wed Nov 19, 8:11AM CST
Stock futures fell out of flat trade to moderate losses ahead of Wednesday's open after a mixed read on October homebuilding activity. Dow futures slumped 18.8 points below fair market value. Nasdaq 100 futures traded down 6.3 points. S&P 500 futures...
SPLS: 13.90 (+1.14), LEJU: 12.23 (-1.93), TSLA: 248.07 (-9.63), FCAU: 12.29 (-0.52), LITB: 7.93 (+0.29), TTM: 46.58 (-0.58), DL: 17.98 (+3.01), VA: 36.13 (-0.92), TGT: 72.45 (+4.94), GM: 32.20 (-0.07), AGIO: 95.61 (+11.80), LOW: 62.37 (+3.84), HMC: 31.17 (-0.48), EJ: 8.67 (-0.86), PETM: 77.21 (+3.59)

Agios leukemia drug candidate shows clinical activity in Phase 1 trial
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 8:01AM CST

AGIO: 95.61 (+11.80)

Agios Cancer 'Metabolism' Drug Clears Bone Marrow of Leukemic Cells
at The Street - Tue Nov 18, 5:02PM CST
The experimental drug from Agios, designed to attack the "metabolism" of cancer cells, has demonstrated early but strong clinical responses in a study involving patients with advanced leukemia.
AGIO: 95.61 (+11.80), CELG: 107.56 (+0.78)

Agios Pharmaceuticals Announces Early Phase 1 Data Showing Clinical Activity of AG-120 as a Single Agent in Advanced Acute Myeloid Leukemia (AML)
GlobeNewswire - Tue Nov 18, 5:01PM CST
-Significant Clinical Responses and Reduction of 2HG Biomarker Provide Early Validation of Mutant IDH1 as a Therapeutic Target in AML -
AGIO: 95.61 (+11.80)

Jim Cramer Says to Buy Six Flags, Avoid SeaWorld Entertainment
at The Street - Wed Nov 12, 1:20PM CST
TheStreet's Jim Cramer says investors shouldn't be tricked by SeaWorld's attractive dividend yield. Instead, stick with Six Flags Entertainment.
SEAS: 17.06 (unch), SIX: 40.07 (-0.73), AGIO: 95.61 (+11.80)

Nasdaq stocks posting largest percentage increases
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
ICUI: 83.23 (-2.33), OREX: 5.72 (+0.10), PCMI: 8.95 (+0.16), CYAN: 7.35 (-0.49), ACHN: 13.19 (-0.12), TGTX: 14.70 (-0.07), AGIO: 95.61 (+11.80), LIOX: 5.02 (-0.12), SAJA: 5.75 (-0.22), PLNR: 7.20 (-0.19)

Biotech Weekly: When Mid Caps Are Priced Nearly For Perfection
Daniel Ward - at Seeking Alpha - Mon Nov 10, 9:28AM CST

XBI: 172.16 (+0.78), SLXP: 106.16 (+0.77), ICPT: 156.71 (-5.79), IBB: 296.33 (+1.08), AGIO: 95.61 (+11.80)

Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 08, 6:31AM CST

AGIO: 95.61 (+11.80)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:14AM CST

BEBE: 2.57 (unch), ANET: 76.88 (+0.08), TKMR: 16.45 (+0.08), ORBC: 6.39 (+0.05), MDRX: 12.08 (-0.12), RMTI: 10.09 (-0.19), CTIC: 2.23 (-0.05), SHLD: 34.88 (-1.03), UBNT: 29.57 (-0.02), RIG: 25.35 (-0.50), KGC: 2.90 (-0.06), APT: 2.83 (+0.10), ANF: 29.11 (+0.17), MITK: 3.91 (-0.05), ZNGA: 2.70 (-0.01), CNET: 1.82 (-0.04), KING: 15.97 (-0.13), NETE: 1.34 (-0.01), SLXP: 106.16 (+0.77), RPRX: 9.14 (-0.05), NADL: 3.31 (-0.66), PGNX: 6.51 (-0.03), AVNR: 13.90 (+0.20), FSLR: 48.67 (-0.79), DVA: 74.79 (-0.44), NDLS: 22.48 (-0.17), ICPT: 156.71 (-5.79), AGIO: 95.61 (+11.80), PLNR: 7.20 (-0.19)

Agios Pharmaceuticals EPS of $0.10
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:11AM CST

AGIO: 95.61 (+11.80)

Agios Pharmaceuticals posts 3Q profit
Automated Insights - Fri Nov 07, 6:09AM CST
CAMBRIDGE, Mass. (AP) _ Agios Pharmaceuticals Inc. (AGIO) on Friday reported earnings of $3.7 million, or 10 cents per share, in its third quarter.
AGIO: 95.61 (+11.80)

Agios Pharmaceuticals Reports Third Quarter 2014 Financial Results
GlobeNewswire - Fri Nov 07, 6:00AM CST
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today reported business highlights and financial results for the third quarter ended September 30, 2014.
AGIO: 95.61 (+11.80)

Notable earnings before Friday’s open
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:30PM CST

BAM: 49.65 (-0.23), ERF: 15.08 (-0.07), LXP: 10.84 (-0.13), PGEM: 12.34 (-0.09), CCOI: 35.13 (-0.02), TTI: 8.02 (-0.14), SJI: 56.49 (-0.06), NXST: 46.51 (-0.89), VSAT: 65.75 (+0.21), MT: 12.26 (-0.19), LXU: 33.93 (+0.20), HUM: 136.84 (-2.45), PGNX: 6.51 (-0.03), MHR: 4.64 (+0.02), CTB: 32.60 (+0.08), IDRA: 2.55 (+0.07), ISIS: 50.60 (+0.89), BPL: 81.60 (+0.20), SSP: 19.55 (-0.09), AGIO: 95.61 (+11.80), EBIX: 15.99 (-0.24)

Will Agios (AGIO) Disappoint in the Q3 Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 4:10PM CST
Agios (AGIO), which is scheduled to report third-quarter results on Nov 7, had delivered a negative earnings surprise of 14.89% in the last quarter.
MNK: 85.02 (-3.78), RNA: 11.51 (+0.01), AGIO: 95.61 (+11.80), CELG: 107.54 (+0.76)

Agios Pharmaceuticals to Present Clinical and Preclinical Data at the 2014 American Society of Hematology Annual Meeting
GlobeNewswire - Thu Nov 06, 8:46AM CST
New Data from Ongoing Phase 1 AG-221 Trial Accepted for Oral Presentation
AGIO: 95.61 (+11.80)

Critical Alerts For LinkedIn, Imperva Inc, Norfolk Southern, Halliburton and Agios Pharmaceuticals Released By InvestorsObserver
PR Newswire - Mon Nov 03, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for LNKD, IMPV, NSC, HAL and AGIO.
NSC: 114.86 (-0.52), LNKD: 220.27 (-0.80), HAL: 48.06 (-0.48), AGIO: 95.61 (+11.80), IMPV: 41.97 (-0.56)

Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 102.09 (-1.62), CLVS: 49.01 (-4.77), ARWR: 5.87 (-0.08), ACHN: 13.19 (-0.12), MRK: 59.55 (-0.34), RTRX: 8.48 (-0.55), RGLS: 16.83 (-1.29), EPZM: 22.91 (-0.52), AGIO: 95.51 (+11.70), RMTI: 10.09 (-0.19), ARNA: 4.15 (-0.16), KERX: 15.35 (-0.19)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Victory Capital Faces Legal Scrutiny Over $7B Deal

Victory Capital's $7 Billion Gamble Under the Microscope New day, new twist in the financial soap opera we call mergers and acquisitions. This time, the spotlight shines on Victory Capital Holdings, Inc. (NASDAQ: VCTR) and its big-dollar dance to acquire First Eagle for a whopping $7 billion. Now, Juan Monteverde, Esq., and his team over at Monteverde & Associates PC have...

Qapture Expands Global DeFi Reach with Key Acquisitions

Qapture Investments just made a move in the digital finance space that's promising to turn some heads. From acquiring Flammarion Partners to snapping up Hermetik Trading's DeFi strategies, this Bermuda-based investment manager isn't here to play. Led by Frederick Pye, the firm's gearing up for an industry takeover by blending regulation with innovative digital finance...

TVEyes Archive+: Revolutionizing Media Intelligence

TVEyes Archive+ Takes Media Intelligence to New Heights Dishing out another update here, folks. TVEyes, the media intelligence powerhouse, just kicked off something that's got the potential to change the strategic media game—they call it Archive+. This tool isn’t just plundering old tapes; we're talking nearly two damn decades worth of historical broadcasts and...

Vertiv's Bold $1.45B Buyout to Enhance AI Data Centers

Vertiv Snatches Up UtilityInnovation Group for $1.45 Billion Throw a stone into the tech sector, and it's bound to hit something about AI or data centers these days. Well, Vertiv Holdings Co. (NYSE: VRT) has made a splash by announcing a meaty $1.45 billion transaction to acquire UtilityInnovation Group (UIG). This move isn't just a bid to dust off the company's resume;...

Backroads Sets 2027 Egypt Tour with Active Adventures

Backroads Brings Adventure Travel to Egypt in 2027 There's an entirely fresh way to get your kicks by the pyramids, and it's coming straight from Backroads, the bigwig of active travel. They're rolling out a Multi-Adventure Tour in the heart of Egypt for 2027. It's got all the bells and whistles: hiking, biking, and kayaking, packaged with a side of luxury at posh hotels...

Elbphilharmonie Hamburg: 10th Anniversary Marks Milestone

Elbphilharmonie's Impact on Hamburg's Cultural Landscape Here we are, staring down the first decade of the Elbphilharmonie, and boy, if that isn't a testament to sticking your neck out for culture, I don't know what is. Opened back on January 11, 2017, this concert hall started as just another controversial project, folks wagging tongues about costs and ambition. But...

ZERO Fresh Start: RAVEN2's New Era Begins Sept 15

What's the Big Deal with ZERO? Alright, so here we go, folks—Netmarble's strapping in with their latest server for RAVEN2, and it's called ZERO. Ever heard of fresh starts? ZERO is exactly that. This isn't your usual server shuffle. Lads and ladies who've felt the grind’ll tell you, ZERO's introducing a slew of changes you might want to sit up for. Pre-registration's...

Intrigue Over Guadalupe River Property Bid

Straight up, a chance like this doesn't float by every day. The Guadalupe River portfolio, with its mix of entertainment, hospitality, and commercial assets up for grabs in New Braunfels, Texas, is the talk of the investor town. If you've got deep pockets and a keen eye for opportunities, you're gonna want a piece of this pie before the September 22 bid deadline hits. The...

Plan A Bets on AI in High-Stakes M&A Arena

Digging Deeper with AI in M&A Deals Picture this: you’re at the table with a fat corporate M&A deal, eyes darting as you decipher numbers and nods, when out swings Plan A Technologies with their new ace up their sleeve—a stealth AI assessment tool armed to sharpen their technical due diligence. Unmasking the Tech Jigsaw Las Vegas-based Plan A Technologies hasn't just...

Kevin Hart & Pragmatic Play Revamp Live Casino Scene

Where Comedy Meets Chances You've got Kevin Hart, larger than life, and then you've got Pragmatic Play—a key player in iGaming. Put them together and you've got an event that might turn the usual casino lights into a full-blown spotlight. They're not just throwing dice, they're shaking up the market with potential way beyond what meets the eye. Okay, so here's the...